 Number of participating centers: grafter centers of Ile-de-France and Hospital Edouard HERRIOT to Lyon, CHU of Nantes, CHU of Poitiers so 10 centers. The study duration will be 42 months, with an inclusion period of 36 months and a follow-up period of 6 months from the last inclusion. If the study gives expected results, a compared phase III trial will be considered for the treatment of CMV infections and a Phase III for the treatment of adenoviral infection. 